NASDAQ:RCM R1 RCM Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding R1 RCM Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.08 -0.04 (-0.25 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$15.76Now: $16.08▼$17.6650-Day Range$13.67MA: $15.04▼$17.0952-Week Range$7.12Now: $16.08▼$17.66Volume23.22 million shsAverage Volume1.23 million shsMarket Capitalization$1.86 billionP/E Ratio160.82Dividend YieldN/ABeta0.69 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers. The company also provides modular services comprising physician advisory services, which assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; and revenue capture services, including charge capture, charge description master maintenance, and pricing services. It serves healthcare providers, including health systems and hospitals, physicians groups, and municipal and private emergency medical service providers, as well as intermountain homecare, hospice and palliative care, and durable medical equipment and infusion therapy business. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was founded in 2003 and is headquartered in Chicago, Illinois.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingR1 RCM has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.40, R1 RCM has a forecasted downside of 4.2% from its current price of $16.08.Amount of Analyst CoverageR1 RCM has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Community Rank Outperform VotesR1 RCM has received 216 “outperform” votes. (Add your “outperform” vote.)Underperform VotesR1 RCM has received 317 “underperform” votes. (Add your “underperform” vote.)Community SentimentR1 RCM has received 59.47% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about R1 RCM and other stocks. Vote “Outperform” if you believe RCM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RCM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldR1 RCM does not currently pay a dividend.Dividend GrowthR1 RCM does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, R1 RCM insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,107,677.00 in company stock.Percentage Held by Insiders60.50% of the stock of R1 RCM is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for R1 RCM are expected to grow by 182.35% in the coming year, from $0.17 to $0.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of R1 RCM is 160.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.09.Price to Earnings Ratio vs. SectorThe P/E ratio of R1 RCM is 160.82, which means that it is trading at a more expensive P/E ratio than the Finance sector average P/E ratio of about 15.52.Price to Earnings Growth RatioR1 RCM has a PEG Ratio of 9.06. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioR1 RCM has a P/B Ratio of 100.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.28 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Management services Sub-IndustryHealth Care Services SectorFinance Current SymbolNASDAQ:RCM Previous SymbolNYSE:RCM CUSIP00438V10 CIK1472595 Webwww.r1rcm.com Phone312-324-7820Debt Debt-to-Equity Ratio13.74 Current Ratio1.27 Quick Ratio1.27Price-To-Earnings Trailing P/E Ratio160.82 Forward P/E Ratio94.59 P/E Growth9.06 Sales & Book Value Annual Sales$1.19 billion Price / Sales1.57 Cash Flow$0.61 per share Price / Cash Flow26.33 Book Value$0.16 per share Price / Book100.50Profitability EPS (Most Recent Fiscal Year)($0.08) Net Income$12 million Net Margins4.02% Return on Equity182.08% Return on Assets5.14%Miscellaneous Employees22,500 Outstanding Shares115,579,000Market Cap$1.86 billion Next Earnings Date11/3/2020 (Estimated) OptionableNot Optionable $16.08 -0.04 (-0.25 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RCM News and Ratings via Email Sign-up to receive the latest news and ratings for RCM and its competitors with MarketBeat's FREE daily newsletter. R1 RCM (NASDAQ:RCM) Frequently Asked Questions How has R1 RCM's stock been impacted by COVID-19? R1 RCM's stock was trading at $10.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RCM stock has increased by 58.3% and is now trading at $16.08. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of R1 RCM? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for R1 RCM. When is R1 RCM's next earnings date? R1 RCM is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for R1 RCM. How were R1 RCM's earnings last quarter? R1 RCM Inc (NASDAQ:RCM) posted its quarterly earnings results on Tuesday, August, 4th. The healthcare provider reported $0.03 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.07 by $0.04. The healthcare provider had revenue of $314.70 million for the quarter, compared to analysts' expectations of $304.94 million. R1 RCM had a return on equity of 182.08% and a net margin of 4.02%. The business's revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period last year, the company earned ($0.09) earnings per share. View R1 RCM's earnings history. What guidance has R1 RCM issued on next quarter's earnings? R1 RCM updated its FY 2020 Pre-Market earnings guidance on Tuesday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.22-1.25 billion, compared to the consensus revenue estimate of $1.21 billion. What price target have analysts set for RCM? 5 brokerages have issued twelve-month price targets for R1 RCM's stock. Their forecasts range from $12.00 to $18.00. On average, they anticipate R1 RCM's stock price to reach $15.40 in the next twelve months. This suggests that the stock has a possible downside of 4.2%. View analysts' price targets for R1 RCM. Are investors shorting R1 RCM? R1 RCM saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 3,730,000 shares, a decrease of 11.4% from the August 15th total of 4,210,000 shares. Based on an average daily trading volume, of 967,400 shares, the short-interest ratio is currently 3.9 days. View R1 RCM's Short Interest. Who are some of R1 RCM's key competitors? Some companies that are related to R1 RCM include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors. What other stocks do shareholders of R1 RCM own? Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.Com (JD), Baozun (BZUN), Marvell Technology Group (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Inseego (INSG), Model N (MODN), Advanced Micro Devices (AMD) and BioXcel Therapeutics (BTAI). Who are R1 RCM's key executives? R1 RCM's management team includes the following people: Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 48)Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 49)Mr. Richard B. Evans Jr., Sr. VP, Interim CFO, Corp. Controller & Chief Accounting Officer (Age 51)Mr. Atif A. Rahim, Sr. VP of Investor Relations & Bus. Devel.Mr. Corey Perman, Exec. VP of Compliance & Risk What is R1 RCM's stock symbol? R1 RCM trades on the NASDAQ under the ticker symbol "RCM." Who are R1 RCM's major shareholders? R1 RCM's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Copper Rock Capital Partners LLC (51.26%), Vanguard Group Inc. (4.63%), Paradigm Capital Management Inc. NY (3.91%), FMR LLC (2.54%), Bank of New York Mellon Corp (2.18%) and Glenmede Trust Co. NA (1.70%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli, Charles J Ditkoff, Joseph Gerard Flanagan and Michael C Feiner. View institutional ownership trends for R1 RCM. Which major investors are selling R1 RCM stock? RCM stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Glenmede Trust Co. NA, Copper Rock Capital Partners LLC, Federated Hermes Inc., Falcon Point Capital LLC, Neuberger Berman Group LLC, Two Sigma Advisers LP, and AlphaCrest Capital Management LLC. View insider buying and selling activity for R1 RCM. Which major investors are buying R1 RCM stock? RCM stock was acquired by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Nuveen Asset Management LLC, Marshall Wace North America L.P., Marshall Wace LLP, Bank of New York Mellon Corp, Point72 Asset Management L.P., Vanguard Group Inc., and Assenagon Asset Management S.A.. Company insiders that have bought R1 RCM stock in the last two years include Albert Rene Zimmerli, and Joseph Gerard Flanagan. View insider buying and selling activity for R1 RCM. How do I buy shares of R1 RCM? Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is R1 RCM's stock price today? One share of RCM stock can currently be purchased for approximately $16.08. How big of a company is R1 RCM? R1 RCM has a market capitalization of $1.86 billion and generates $1.19 billion in revenue each year. The healthcare provider earns $12 million in net income (profit) each year or ($0.08) on an earnings per share basis. R1 RCM employs 22,500 workers across the globe. What is R1 RCM's official website? The official website for R1 RCM is www.r1rcm.com. How can I contact R1 RCM? R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at 312-324-7820 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
